UK markets got off to a strong start to the new trading week as the FTSE 100 advanced almost 70 points, around 1%, in early deals to 6,657.14, taking its cue from Asia, which enjoyed a buoyant opening session.Stimulus and vaccine roll-out optimism provided international markets with the early shot in the arm. Japan provided much of the fuel, with the Nikkei 225 broke through the 30,000 point...

Biotechnology hopeful Oncimmune (ONC:AIM) hopes to make a 'significant impact' in tackling cancer in China. The disease is the biggest cause of death among the world's largest populated nation, with lung cancer the biggest killer, with more than 700,000 diagnoses every year.Oncimmune has developed an early cancer detection technology, called EarlyCDT that uses a blood sample. Today's...

The FTSE 100's end of year rally has failed to extend to 2018 as the blue chip index trades 27 points lower on the first of trading in the New Year. At 8.45am, it was 0.36% lower at 7,660.Miners, oil producers and insurers are some of the worst FTSE 100 performers. Among the stragglers is oil giant BP (BP.) which dips 0.4% to 520.8p after saying it will incur an approximate $1.5bn one-off...

FTSE 250 midcap stocks open lower by almost 1% after a profit warning from economic bellwether Clarkson (CKN).The shipping services outfit trades 20% lower at £17.53 as it reports its Clarksea Index, which measures global shipping activity, was 30% lower in the first half of 2016 compared to a year earlier.As a result, profit at Clarkson will be 'materially lower' in its 2016 financial year,...

The company behind a revolutionary test that screens for cancer has joined the stock market. Oncimmune (ONC:AIM) hit the headlines earlier this year when an NHS trial featuring its EarlyCDT-Lung blood test was picked up by national media.The firm has now raised £11 million to expand its product range and give EarlyCDT-Lung a push into new markets including Asia.Shares in Oncimmune nudged...